Clinical Trial

Hyperkalemia Quality Improvement Program (HK-QIP) Study

Study acronym: HK-QIP
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, multi-center, single-arm study to evaluate the impact of implementation of guideline determined medical therapy (GDMT) for quality control improvement in non-dialysis chronic kidney disease (CKD-ND) patients, as well as provide evidence for standard hyperkalemia management with RAASi optimization in China CKD-ND patients.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-09
notable Primary completion pushed: 2027-11-03 -> 2027-12-11 2026-05-09
minor Completion pushed: 2027-11-03 -> 2027-12-11 2026-05-09
Trial Details
NCT Number NCT06884267
Lead Sponsor AstraZeneca
Conditions Hyperkalemia
Enrollment 1,000 participants
Start Date 2025-06-25
Primary Completion 2027-12-11 (estimated)
Study Completion 2027-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-08